FBD Biologics Limited
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors (NCT06487624) | FBD Biologics Limited | 2025-04-02 |
| Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors (NCT06771622) | FBD Biologics Limited | 2025-03-13 |
| A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors (NCT05892718) | FBD Biologics Limited | 2023-10-02 |
Track FBD Biologics Limited automatically
Every clearance here is in the API, with alerts when new ones post.